5.21 USD
-0.37 (-6.63%)
5.25 USD
+0.04 (+0.77%)
Taking everything into account, MNKD scores 5 out of 10 in our fundamental rating. MNKD was compared to 525 industry peers in the Biotechnology industry. MNKD has only an average score on both its financial health and profitability. MNKD is not priced too expensively while it is growing strongly. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- In the past year MNKD was profitable.
- MNKD had a positive operating cash flow in the past year.
- In the past 5 years MNKD reported 4 times negative net income.
- The reported operating cash flow has been mixed in the past 5 years: MNKD reported negative operating cash flow in multiple years.
1.2 Ratios
- MNKD has a better Return On Assets (5.81%) than 92.38% of its industry peers.
- MNKD has a better Return On Invested Capital (18.48%) than 97.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROIC | 18.48% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Profit Margin value of 9.16%, MNKD belongs to the best of the industry, outperforming 90.86% of the companies in the same industry.
- MNKD's Operating Margin of 27.48% is amongst the best of the industry. MNKD outperforms 96.38% of its industry peers.
- With an excellent Gross Margin value of 78.49%, MNKD belongs to the best of the industry, outperforming 84.76% of the companies in the same industry.
- In the last couple of years the Gross Margin of MNKD has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so MNKD is creating value.
- MNKD has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MNKD has more shares outstanding
- Compared to 1 year ago, MNKD has an improved debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -5.40, we must say that MNKD is in the distress zone and has some risk of bankruptcy.
- MNKD has a worse Altman-Z score (-5.40) than 61.90% of its industry peers.
- The Debt to FCF ratio of MNKD is 8.39, which is on the high side as it means it would take MNKD, 8.39 years of fcf income to pay off all of its debts.
- The Debt to FCF ratio of MNKD (8.39) is better than 91.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Altman-Z | -5.4 |
ROIC/WACC2.16
WACC8.56%
2.3 Liquidity
- A Current Ratio of 3.29 indicates that MNKD has no problem at all paying its short term obligations.
- MNKD's Current ratio of 3.29 is on the low side compared to the rest of the industry. MNKD is outperformed by 60.76% of its industry peers.
- MNKD has a Quick Ratio of 3.04. This indicates that MNKD is financially healthy and has no problem in meeting its short term obligations.
- MNKD has a Quick ratio of 3.04. This is in the lower half of the industry: MNKD underperforms 61.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 |
3. Growth
3.1 Past
- MNKD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 174.00%, which is quite impressive.
- The Revenue has grown by 17.44% in the past year. This is quite good.
- Measured over the past years, MNKD shows a very strong growth in Revenue. The Revenue has been growing by 35.29% on average per year.
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
3.2 Future
- Based on estimates for the next years, MNKD will show a very strong growth in Earnings Per Share. The EPS will grow by 52.41% on average per year.
- The Revenue is expected to grow by 18.41% on average over the next years. This is quite good.
EPS Next Y-2.25%
EPS Next 2Y23.69%
EPS Next 3Y46.43%
EPS Next 5Y52.41%
Revenue Next Year20.77%
Revenue Next 2Y22.88%
Revenue Next 3Y19.82%
Revenue Next 5Y18.41%
3.3 Evolution
- Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 37.21 indicates a quite expensive valuation of MNKD.
- Based on the Price/Earnings ratio, MNKD is valued cheaper than 92.00% of the companies in the same industry.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, MNKD is valued a bit more expensive.
- MNKD is valuated quite expensively with a Price/Forward Earnings ratio of 42.57.
- Based on the Price/Forward Earnings ratio, MNKD is valued cheaper than 90.86% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, MNKD is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.21 | ||
| Fwd PE | 42.57 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MNKD indicates a rather cheap valuation: MNKD is cheaper than 94.48% of the companies listed in the same industry.
- Based on the Price/Free Cash Flow ratio, MNKD is valued cheaply inside the industry as 93.14% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.87 | ||
| EV/EBITDA | 16.22 |
4.3 Compensation for Growth
- MNKD's earnings are expected to grow with 46.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.69%
EPS Next 3Y46.43%
5. Dividend
5.1 Amount
- MNKD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
5.21
-0.37 (-6.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/bmo
Earnings (Next)02-24 2026-02-24/amc
Inst Owners57.07%
Inst Owner Change0.09%
Ins Owners1.59%
Ins Owner Change1.09%
Market Cap1.60B
Revenue(TTM)313.79M
Net Income(TTM)28.75M
Analysts85.33
Price Target9.8 (88.1%)
Short Float %6.77%
Short Ratio5.56
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)53.26%
Min EPS beat(2)-100%
Max EPS beat(2)206.52%
EPS beat(4)1
Avg EPS beat(4)19.34%
Min EPS beat(4)-100%
Max EPS beat(4)206.52%
EPS beat(8)2
Avg EPS beat(8)-31.68%
EPS beat(12)5
Avg EPS beat(12)-2.87%
EPS beat(16)6
Avg EPS beat(16)-4.99%
Revenue beat(2)1
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-4.55%
Max Revenue beat(2)0.33%
Revenue beat(4)3
Avg Revenue beat(4)-0.74%
Min Revenue beat(4)-4.55%
Max Revenue beat(4)0.9%
Revenue beat(8)6
Avg Revenue beat(8)1.65%
Revenue beat(12)8
Avg Revenue beat(12)2.45%
Revenue beat(16)11
Avg Revenue beat(16)3.58%
PT rev (1m)6.13%
PT rev (3m)-9.08%
EPS NQ rev (1m)-11.11%
EPS NQ rev (3m)-42.51%
EPS NY rev (1m)-1.71%
EPS NY rev (3m)-27.47%
Revenue NQ rev (1m)0.28%
Revenue NQ rev (3m)12.17%
Revenue NY rev (1m)-0.12%
Revenue NY rev (3m)4.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.21 | ||
| Fwd PE | 42.57 | ||
| P/S | 5.1 | ||
| P/FCF | 36.87 | ||
| P/OCF | 32.75 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 16.22 |
EPS(TTM)0.14
EY2.69%
EPS(NY)0.12
Fwd EY2.35%
FCF(TTM)0.14
FCFY2.71%
OCF(TTM)0.16
OCFY3.05%
SpS1.02
BVpS-0.15
TBVpS-0.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.81% | ||
| ROE | N/A | ||
| ROCE | 22.37% | ||
| ROIC | 18.48% | ||
| ROICexc | 48.2% | ||
| ROICexgc | 50.4% | ||
| OM | 27.48% | ||
| PM (TTM) | 9.16% | ||
| GM | 78.49% | ||
| FCFM | 13.83% |
ROA(3y)-8.37%
ROA(5y)-20.59%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y13.44%
GM growth 5Y5.99%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 8.39 | ||
| Debt/EBITDA | 3.59 | ||
| Cap/Depr | 64.99% | ||
| Cap/Sales | 1.74% | ||
| Interest Coverage | 9.12 | ||
| Cash Conversion | 51.63% | ||
| Profit Quality | 150.89% | ||
| Current Ratio | 3.29 | ||
| Quick Ratio | 3.04 | ||
| Altman-Z | -5.4 |
F-Score8
WACC8.56%
ROIC/WACC2.16
Cap/Depr(3y)397.13%
Cap/Depr(5y)337.1%
Cap/Sales(3y)10.78%
Cap/Sales(5y)10.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%235%
EPS Next Y-2.25%
EPS Next 2Y23.69%
EPS Next 3Y46.43%
EPS Next 5Y52.41%
Revenue 1Y (TTM)17.44%
Revenue growth 3Y55.86%
Revenue growth 5Y35.29%
Sales Q2Q%17.2%
Revenue Next Year20.77%
Revenue Next 2Y22.88%
Revenue Next 3Y19.82%
Revenue Next 5Y18.41%
EBIT growth 1Y48.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y237.18%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y386.62%
OCF growth 3YN/A
OCF growth 5YN/A
MANNKIND CORP / MNKD FAQ
What is the fundamental rating for MNKD stock?
ChartMill assigns a fundamental rating of 5 / 10 to MNKD.
Can you provide the valuation status for MANNKIND CORP?
ChartMill assigns a valuation rating of 5 / 10 to MANNKIND CORP (MNKD). This can be considered as Fairly Valued.
Can you provide the profitability details for MANNKIND CORP?
MANNKIND CORP (MNKD) has a profitability rating of 5 / 10.
What are the PE and PB ratios of MANNKIND CORP (MNKD) stock?
The Price/Earnings (PE) ratio for MANNKIND CORP (MNKD) is 37.21 and the Price/Book (PB) ratio is -35.91.